The Specific α1-Adrenergic Receptor Antagonist Prazosin Influences the Urine Proteome

Mindi Zhao¹, Jianqiang Wu¹, Youhe Gao¹,²*

¹ Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, China, ² Department of Biochemistry and Molecular Biology, Beijing Normal University, Gene Engineering and Biotechnology Beijing Key Laboratory, Beijing, China

Abstract

Urine, reflecting many changes in the body, is a better source than blood for biomarker discovery. However, even under physiological conditions, the urine proteome often varies. Understanding how various regulating factors affect urine proteome helps link changes to urine proteome with urinary biomarkers of physiological conditions as well as corresponding diseases. To evaluate the possible impact of α1-adrenergic receptor on urine proteome, this study investigated effects of the specific inhibitor prazosin on the urine proteome in a rat model by using tandem mass tagging and two-dimensional liquid chromatography-tandem mass spectrometry. A total of 775 proteins were identified, approximately half of which were influenced by prazosin treatment, indicating that the sympathetic nervous system exerts a significant impact on urine proteome. Eight significantly changed proteins were previously annotated as urinary candidate biomarkers. Angiotensinogen, haptoglobin, and beta-2 microglobulin, which were reported to be associated with blood pressure, were validated via Western blot. Prazosin is widely used in clinical practice; thus, these protein changes should be considered when studying corresponding diseases such as hypertension, post-traumatic stress disorder and benign prostatic hyperplasia. The related physiological activities of α1-receptors, controlling blood pressure and fear response might significantly affect the urine proteome and warrant further biomarker studies.

Introduction

Biomarkers are the measurable changes associated with a physiological or pathophysiological process [1]. As a better biomarker source than blood, urine reflect multiple changes in the body, and is affected by many factors such as physiological conditions, age, gender, hormones and diseases [2]. It is difficult to determine which factors induce complicated urine proteome changes. Elucidating how various regulating factors affect the urine proteome allows the association of changes to the urine proteome with urinary biomarkers of physiological conditions in
addition to diseases and their corresponding mechanisms. The urine proteome can be affected by anesthetics [3], which suggested that urinary proteins might be regulated by the central nervous system; thus, changes in central nerve system are reflected in urine. The sympathetic nervous system is one of two important components of the autonomic nervous system. Changes resulting from sympathetic nervous system activation or inhibition are often present in many diseases. However, whether the sympathetic nervous system can regulate the urine proteome has not been studied.

A1-receptors represent attractive and tangible targets for therapeutic intervention and have been shown to mediate sympathetic nervous system activity [4]. Antagonism of α1 receptors results in smooth muscle relaxation and a decrease in total peripheral resistance [5]. Prazosin, a specific α1-adrenergic receptor antagonist, has been used alone or with other medications to treat cardiovascular diseases such as hypertension and congestive heart failure[6, 7]. More recently, prazosin was suggested as a treatment for post-traumatic stress disorder (PTSD), which is a common disease with a comparatively high morbidity rate and severe comorbidities. Prazosin has been demonstrated to be safe and effective for the treatment of nightmares and sleep disturbances associated with PTSD [8], which might be partly because α1-adrenergic receptors are involved in fear response behaviors as well as startle and sleep response in the brain, decreasing levels of norepinephrine in the central nervous system[9]. In the urinary system, studies have indicated that α1-adrenergic receptor antagonists play important roles in modulating sympathetic and parasympathetic activity of the urinary bladder[10]. These α-adrenergic blockers, especially those that are specific to α-1a, have been implicated and used in the treatment of lower urinary tract symptoms such as symptomatic benign prostatic hyperplasia and urinary dysfunction in women[10, 11]. The α-1a receptor is actively involved in these diseases; thus, studying the specific antagonist prazosin might help in understanding the effects of the α-1a receptor on the urine proteome and provide clues into the regulatory mechanism of the urine proteome.

A prazosin study in rats using liquid chromatography-mass spectrometry (LC-MS) platform was performed. An animal model was used to limit the number of confounding factors and enable observation of associated changes from fewer samples. Urinary protein identification was performed in six samples that before and after prazosin-treatment, and the protein changes were then validated in the remaining twelve samples.

Materials and Methods

Experimental rats

18 male Sprague-Dawley rats (12 weeks old) were purchased from the Institute of Laboratory Animal Science, Chinese Academy of Medical Science & Peking Union Medical College. The experiment was approved by the Institute of Basic Medical Sciences Animal Ethics Committee, Peking Union Medical College (Animal Welfare Assurance Number: ACUC-A02-2014-007). The study was performed according to guidelines developed by the Institutional Animal Care and Use Committee of Peking Union Medical College. All animals were maintained with free access to standard laboratory diet and water with a 12 h light–dark cycle under controlled indoor temperature (22 ± 1°C) and humidity (65–70%) conditions. Rats were sacrificed under deep sodium pentobarbital anesthesia after feeding on the last day and all efforts were made to minimize suffering.

Administration of Prazosin

All rats were randomly divided into two groups: one group was administered daily prazosin at 10 mg/kg/day via oral gavage (9 rats); the other control group (9 rats) received treatment via
gavage with a matching volume of 0.9% NaCl saline vehicle. Before the prazosin treatment and at the seventh day after prazosin treatment, all rats were individually placed in the metabolic cages for four hours. Then the four-hour urine samples were used for proteomics analysis. Blood samples were collected from each individual to monitor changes in low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, cholesterol (Jiancheng Bioengineering Institute, China) and blood glucose (Roche, Germany). The experiment was conducted in two phases: for the discovery phase, differential urinary protein identification was performed in six independent samples that were collected respectively before and after prazosin treatment from three rats, and for the validation phase, samples were obtained from the twelve remaining samples (six before prazosin treatment and the other six after that treatment).

Urine sample preparation and tandem mass tag (TMT) labeling

Urine was centrifuged at 2000 g for 30 min immediately after collection. Three volumes of acetone were added after removing the pellets, and the samples were precipitated at 4°C. Then, 8 M urea, 2 M thiourea, 25 mM dithiothreitol and 50 mM Tris were used to re-dissolve the pellets. The protein concentration of each sample was measured by the Bradford protein assay. The proteins were digested with trypsin (Promega, USA) using filter-aided sample preparation methods[12]. Briefly, 200 μg of protein were loaded on the 10kD filter unit (Pall, USA), and 200 μl UA (8 M urea in 0.1 M Tris–HCl, pH 8.5) was added to the filter unit and centrifuged at 14,000g for 40 min. Then 200 μl ABC (0.05M NH₄HCO₃ in water) was added and the centrifuged. 100 μl dithiothreitol solution (0.02 M dithiothreitol in ABC) was added to the filter unit and incubated for 1 hour. Centrifuge the filter units at 14,000g for 30 min. 100 μl iodoacetamide solution (0.05 M iodoacetamide in ABC) was added to filter unit and incubated in the dark for 40 min. Centrifuge the filter units at 14,000g for 30 min. Then the concentrate was dissolved in 50 mM NH₄HCO₃. Proteins were digested with trypsin (4 μg) at 37°C overnight. The digested peptides were desalted using Oasis HLB cartridges (Waters, USA).

The six urinary samples before and after the prazosin administration were individually labeled with 126, 127, 128, 129, 130 and 131 TMT reagents according to the manufacturer's protocol (Thermo Fisher Scientific, Germany) and then analyzed with two dimensional (2D) LC/MS/MS.

Reverse Phase Liquid Chromatography (RPLC)

All samples were fractionated using offline high-pH RPLC columns (XBridge, C18, 3.5 μm, 4.6 mm × 250 mm, Part No. 186003943; Waters, USA). The samples were loaded onto the column in buffer A1 (10 mM NH₄FA in H₂O, pH = 10). The elution gradient was 5–30% buffer B1 (10 mM NH₄FA in 90% acetonitrile, pH = 10; flow rate = 1 mL/min) for 60 min. The eluted peptides were collected at one fraction per minute. After lyophilization, the 60 fractions were re-suspended in 0.1% formic acid and concatenated into 30 fractions by combining fractions 1 with 31, 2 with 32, and so on[13].

LC-MS/MS analysis

Each fraction was analyzed three times using a reverse-phase C18 (3 μm, Dr. Maisch, Germany) self-packed capillary LC column (75 μm × 120 mm). The eluted gradient was 5%–30% buffer B (0.1% formic acid in acetonitrile; flow rate 0.3μl/min) for 60 min. The peptides were analyzed using a linear trap quadrupole (LTQ)-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Germany). The MS data were acquired in data-dependent acquisition mode using the following parameters: 300–2,000 m/z range with the resolution set to 60,000; dynamic exclusion was employed with a 60 sec window to prevent the repetitive selection of
the same peptide. Full scans and higher energy collisionally activated dissociation (HCD) scans were acquired in Orbitrap. The normalized collision energy for HCD-MS2 experiments was set to 40%.

**Data processing**

All MS/MS spectra were analyzed using the Mascot search engine (version 2.4.1, Matrix Science, UK), and proteins were identified by searching against the Swissprot_2014_07 databases (taxonomy: Rattus, containing 7,906 sequences). The parameters were set as follows: the carboxymethylation of cysteines and TMT labeling were set as fixed modifications and two missed trypsin cleavage sites were allowed. The precursor mass tolerance was set to 10 ppm, and the fragment mass tolerance was set to 0.05 Da.

Mascot search results were filtered using the decoy database method in Scaffold (version 4.3.2, Proteome Software Inc., Portland, OR). Peptide identifications were accepted if they could be established at greater than 99.0% probability to achieve a false discovery rate (FDR) less than 1.0%. Protein identifications were accepted if they could be established at greater than 99.0% probability to achieve an FDR less than 1.0% and contained at least 2 identified peptides. Protein probabilities were assigned using the Protein Prophet algorithm[14]. Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. Proteins sharing significant peptide evidence were grouped into clusters. Scaffold Q+ was used to quantitate TMT labeling quantification, peptide and protein identifications. Acquired intensities in the experiment were globally normalized across all runs. The statistical test utilized in Scaffold Q+ was permutation test. The calculation type was median, the reference type was average protein reference and the normalization between samples was set "ON". The minimum dynamic range was set to 1%.

**Western Blot**

A total of 20 μg of urinary proteins from each individual sample (six before prazosin administration and six after) were loaded onto a 10% SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane (Whatman, UK). Membranes were incubated overnight at 4°C with primary antibodies against Angiotensinogen (AGT), Haptoglobin (HP), Legumain (LGMN) or Beta-2 microglobulin (B2M) (Abcam, USA). The membranes were then washed and incubated with peroxidase-conjugated anti-rabbit IgG (ZSGB-bio, China) at room temperature for 2 h, and the proteins were visualized using enhanced chemiluminescence (ECL) reagents (Thermo Fisher Scientific, USA). The ECL results were scanned and analyzed using an ImageQuant 400™ Imager (GE Healthcare Life Sciences, USA) and the intensity of each protein band was quantified using Image J analysis software (National Institutes of Health, USA). The intensity of each protein before and after prazosin administration were analyzed by Mann-Whitney test. The unchanged protein “albumin” from MS results was used as loading control.

**Results and Discussion**

**Characterization of prazosin-administered rats**

To investigate the effect of the specific α1-adrenergic receptor antagonist prazosin on the urine proteome, rats were treated separately with prazosin or a vehicle for seven days. The body weight was measured at regular intervals throughout the experiment. The mean body weight at day 7 was 232 g in the prazosin-administered rats and 251 g in the control rats (P value < 0.05). The ten rats in the prazosin-administered group exhibited a slower increase in body weight at day 7
than those in the control group (Fig 1A). Because the α adrenergic agonists were considered to stimulate energy metabolism\[15\], prazosin may have some direct or indirect effects on the body weight.

Studies have reported that the α1-adrenergic blockade was related to the serum lipid levels \[16\], therefore, the serum cholesterol, triglyceride, HDL and LDL levels were measured before and during the prazosin treatment. Consistent with previous studies, the serum LDL was significantly lower (p < 0.001) after seven days of prazosin treatment (Fig 1B). The mean concentration was 0.03 mmol/L, compared with 0.07 mmol/L for the control. However, significant differences were not observed in the serum HDL (2.91 mmol/L, compared with 2.88 mmol/L).
in the control) (Fig 1C), which may have been caused by the short-term prazosin treatment. A significant decrease was observed in the serum cholesterol (0.33 mmol/L, compared with 0.99 mmol/L in the control, P value < 0.05) (Fig 1D). The blood glucose, triglycerides and urine volume were similar between the two groups.

Urine proteome changes

In the discovery phase, urine samples collected from three pairs before and after seven days of prazosin treatment were obtained, respectively, for the TMT-2DLC-MS/MS analysis (Fig 2). The TMT-labeled samples were separated into 30 fractions, and each fraction was analyzed.
three times. All spectra were searched against the Swissprot database, and the resulting data were filtered using Scaffold software for protein identification and quantification. The identified peptides that are shared between two proteins were combined and reported as one protein group. A total of 54,591 spectra corresponding to 867 proteins with ≥ 2 peptides were identified with 1% FDR at the protein level were identified, among them, 775 proteins were quantified by TMT-labeling analysis. All identification and quantitation details are listed in S1 Table.

For all three pairs of samples, most of the proteins exhibited a similar response trend under prazosin administration according to the quantitative mass spectrometric analysis. Of the protein changes, 299 had a P value < 0.05 (statistical test utilized in Scaffold Q+ was a permutation test). Among these proteins, 10 up-regulated proteins showed a 1.50-fold change in each of the three samples that received prazosin, whereas 11 proteins demonstrated a decrease, with a fold change < 0.67. Table 1 depicts the significant protein changes in the urine following the prazosin treatment.

| ID   | Protein Name                                      | MW  | Fold Change 1 | Fold Change 2 | Fold Change 3 | Human ortholog | Biomarker use                  |
|------|--------------------------------------------------|-----|---------------|---------------|---------------|----------------|-------------------------------|
| P02761 | Major urinary protein                            | 21 kD | 2.6 | 2.1 | 3.2 | No | acute renal failure[17] |
| P06866 | Haptoglobin                                      | 39 kD | 2.9 | 3.4 | 2.3 | Yes | diabetic nephropathy[18] |
| P07151 | Beta-2-microglobulin                             | 14 kD | 1.5 | 2   | 1.8 | Yes | acute tubular injury[19]   |
| P01015 | Angiotensinogen                                  | 52 kD | 2.2 | 1.8 | 2.3 | Yes | primary hypertension[20]   |
| P10758 | Lithostathine                                    | 19 kD | 2.1 | 1.8 | 1.7 | Yes | dents disease[19]          |
| Q9R0J8 | Legumain                                         | 49 kD | 1.5 | 1.9 | 1.9 | Yes |                                |
| B0BNN3 | Carbonic anhydrase 1                             | 28 kD | 3.5 | 1.5 | 1.9 | Yes | bladder cancer[21]        |
| P26772 | 10 kDa heat shock protein, mitochondrial         | 11 kD | 2   | 1.6 | 1.8 | Yes |                                |
| P19223 | Carboxypeptidase B                              | 48 kD | 2.1 | 2.2 | 2.3 | Yes |                                |
| P19999 | Mannose-binding protein A                       | 25 kD | 1.9 | 1.7 | 2.4 | No  |                                |
| P14046 | Alpha-1-inhibitor 3                             | 164 kD | 0.5 | 0.6 | 0.6 | Yes |                                |
| Q64319 | Neutral and basic amino acid transport protein rBAT | 79 kD | 0.6 | 0.6 | 0.5 | Yes | protein excretion with sodium loading[22] |
| P14668 | Annexin A5                                       | 36 kD | 0.5 | 0.6 | 0.5 | Yes | acute renal failure[17]    |
| Q9WTW7 | Solute carrier family 23 member 1               | 65 kD | 0.6 | 0.3 | 0.5 | Yes |                                |
| Q06496 | Sodium-dependent phosphate transport protein 2A | 69 kD | 0.5 | 0.6 | 0.4 | Yes |                                |
| Q64602 | Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial | 48 kD | 0.6 | 0.5 | 0.5 | Yes |                                |
| P70502 | Solute carrier organic anion transporter family member 1A3 | 74 kD | 0.6 | 0.6 | 0.5 | Yes |                                |
| O35913 | Cluster of Solute carrier organic anion transporter family member 1A4 | 73 kD | 0.6 | 0.5 | 0.6 | No  |                                |
| O08839 | Mbc box-dependent-interacting protein 1         | 65 kD | 0.6 | 0.6 | 0.5 | Yes |                                |
| Q71MB6 | Solute carrier organic anion transporter family member 4C1 | 79 kD | 0.6 | 0.4 | 0.6 | Yes |                                |
| A4KWA5 | C-type lectin domain family 2 member D2         | 26 kD | 0.6 | 0.6 | 0.5 | Yes |                                |

Table 1. Details of changed urinary proteins identified in the TMT experiment.

doi:10.1371/journal.pone.0164796.t001
The renin-angiotensin system and increase serum angiotensinogen levels[25]. The plasma protein haptoglobin (Hp) has been reported to increase in response to inflammatory stimuli such as infection, injury or malignancy[26]. A previous study also confirmed a relationship between (Hp) phenotypes and blood pressure[27]. Beta-2 microglobulin (B2M) has been proposed as a prognostic factor for various diseases, such as mantle cell lymphoma[28] and acute kidney failure[19]. Similar to the previous two proteins of interest, significantly increased B2M excretion in urine has been observed in patients with severe blood hypertension[29]. All three of these proteins have been associated with blood pressure to some degree. Legumain (LGMN) is known to be positively expressed in many types of human tumors, including ovarian[30] and breast cancer[31], although whether LGMN is related to the effect of the $\alpha_1$-adrenergic receptor remains unknown. Disease-related emotional disturbances might affect the urine proteome via the $\alpha_1$-adrenergic receptor.

Four changed proteins (HP, LGMN, AGT and B2M), which were increased in all three pairs, were selected for further validation in twelve additional individual urine samples via Western Blot, which was performed because of the relevance of these proteins to prazosin-related diseases as well as their relatively high abundance and commercially available antibodies. The expression of all four proteins was consistent with the MS results (Fig 3, the Mann-Whitney test was used to run the statistical analysis). In this study, elevated urinary AGT levels were associated with the prazosin treatment (p value, 0.006; 1.5-fold change). Urinary B2M showed a significant elevation (P value, 0.004; 2.1-fold change). Similarly, the LGMN levels were also significantly increased in the prazosin-administered sample (P value, 0.004; 4.0-fold change). However, HP was not significantly elevated after prazosin administration, but presented an increasing tendency.
Functional annotation

The 299 differentially expressed proteins were analyzed using the IPA tool to assess their association with important biological functions. These proteins were located in extracellular spaces (24%), the cytoplasm (35%) and the plasma membrane (35%) (Fig 4A). The ten canonical signaling pathways with the greatest changes are shown in Fig 4C. The canonical pathway analysis demonstrated that protein changes were highly associated with acute phase response signaling, the γ–glutamyl cycle and the coagulation system. Two representative canonical pathways in the prazosin-treated groups are the γ–glutamyl cycle and glutathione biosynthesis, both of which are important in amino acid biosynthesis and ATP energy metabolism. Glutathione not only protects against nerve damage[32], but also can halt ongoing cycles of oxidative stress[33]. As shown in Fig 4D, the core components of the γ–glutamyl cycle pathway were identified in the prazosin-treated group.

Fig 4. Functional analysis of the protein changes induced by the prazosin treatment. A) Subcellular location. B) AGT network. C) Top ten canonical pathways. The y axis shows the negative log of the p value. D) γ–glutamyl cycle pathway. The molecule marked in red is the protein identified in this study.

doi:10.1371/journal.pone.0164796.g004
The protein changes induced by prazosin might provide insights for further examinations of other pathological changes. As described above, AGT is a core component of the renin-angiotensin system and might be a target of prazosin [25]. The signature protein of AGT was further characterized based on protein–protein interactions constructed using IPA (Fig 4B). The network was divided into three parts according to the functions of the included proteins. Glutamyl aminopeptidase (ENPEP) and ATPase, which are important in energy and glutathione metabolism, are closely related to AGT. The inflammation-related molecules in the network (selectin (SELE), CD44 and intercellular adhesion molecule 1 (ICAM 1)) might be responsible for acute-phase signaling. Another interaction relevant to prazosin was linked to LDL because serum LDL was significantly decreased after the prazosin treatment.

Half of the identified urinary proteins showed an expression change (P < 0.05); thus, prazosin-related diseases such as hypertension, PTSD and fear response might influence the urine proteome and warrant further biomarker studies. Compared with the effects of anesthetics on the nervous system on the urine proteome [3], the protein changes in this study were substantially different and shared only one protein change. Changes in the urine proteome may also be caused by medicines such as diuretics [34] and anticoagulants [35], which indicates that the regulation of urinary proteins is complicated. More complicated urine patterns might represent connections to a greater number of physiological and pathophysiological conditions. This important property of urine increases the likelihood that it is a high-resolution and high-sensitivity biomarker source. Insight into how the various regulating factors affect the urine proteome can be used to associate changes in the urine proteome with urinary biomarkers of physiological conditions and diseases as well as their corresponding mechanisms.

Supporting Information
S1 Table. The identification and quantitation details.
(XLSX)

Author Contributions
Conceptualization: MZ YG.
Data curation: MZ JW.
Formal analysis: MZ.
Funding acquisition: YG.
Investigation: MZ.
Methodology: MZ.
Project administration: MZ.
Resources: MZ.
Software: MZ JW.
Supervision: YG.
Validation: MZ.
Visualization: MZ.
Writing – original draft: MZ.
Writing – review & editing: MZ YG.

References

1. Gao Y. Urine-an untapped goldmine for biomarker discovery? Science China Life sciences. 2013; 56 (12):1145–6. doi: 10.1007/s11427-013-4574-1 PMID: 24271956.

2. Wu J, Gao Y. Physiological conditions can be reflected in human urine proteome and metabolome. Expert review of proteomics. 2015;1–14. doi: 10.1586/14789450.2015.1094380 PMID: 26472227.

3. Zhao M, Li X, Li M, Gao Y. Effects of anesthetics pentobarbital sodium and chloral hydrate on urine proteome. PeerJ. 2015; 3:e813. doi: 10.7717/peerj.813 PMID: 25789206; PubMed Central PMCID: PMC4362303.

4. Piascik MT, Perez DM. Alpha1-adrenergic receptors: new insights and directions. The Journal of pharmacology and experimental therapeutics. 2001; 298(2):403–10. PMID: 11549890.

5. Nash DT. Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism. Clinical cardiology. 1990; 13(11):764–72. PMID: 1980296.

6. Brogden R, Heel R, Speight T, Avery G. Prazosin: A Review of its Pharmacological Properties and Therapeutic Efficacy. Antihypertensive Drugs Today: Springer; 1979. p. 125–69.

7. Romankiewicz J, Brogden R, Heel R, Speight T, Avery G. Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs. 1983; 25(1):6–40. PMID: 6218982.

8. Togno J, Eaton S. Is there a role for prazosin in the treatment of post-traumatic stress disorder? Australian family physician. 2015; 44(9):647–9. PMID: 26488043.

9. Taylor F, Raskind MA. The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian posttraumatic stress disorder. Journal of clinical psychopharmacology. 2002; 22(1):82–5. PMID: 11799347.

10. Lowe FC. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clinical therapeutics. 2004; 26(11):1701–13. doi: 10.1016/j.clinthera.2004.11.006 PMID: 15639685.

11. Boyd K, Hilas O. alpha-adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women. The Annals of pharmacotherapy. 2014; 48(6):711–22. doi: 10.1177/1060028014524174 PMID: 24615630.

12. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nature methods. 2009; 6(5):359–62. doi: 10.1038/nmeth.1322 PMID: 19377485.

13. Wang Y, Yang F, Gritsenko MA, Wang Y, Clauss T, Liu T, et al. Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics. 2011; 11(10):2019–26. doi: 10.1002/pmc.21500348; PubMed Central PMCID: PMC3120047.

14. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Analytical chemistry. 2003; 75(17):4646–58. PMID: 14632076.

15. Subbarao KV, Hertz L. Stimulation of energy metabolism by alpha-adrenergic agonists in primary cultures of astrocytes. Journal of neuroscience research. 1991; 28(3):399–405. doi: 10.1002/jnr.490280312 PMID: 1677429.

16. Fajardo N, Deshaies Y. Long-term alpha1-adrenergic blockade attenuates diet-induced dyslipidemia and hyperinsulinemia in the rat. Journal of cardiovascular pharmacology. 1998; 32(6):913–9. PMID: 9869496.

17. Holly MK, Dear JW, Hu X, Schechter AN, Gladwin MT, Hewitt SM, et al. Biomarker and drug-target discovery using proteomics in a new rat model of sepsis-induced acute renal failure. Kidney international. 2006; 70(3):496–506. doi: 10.1038/sj.ki.5001575 PMID: 16760904; PubMed Central PMCID: PMC2276658.

18. Rao PV, Lu X, Standley M, Pattee P, Neelima G, Girish G, et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes care. 2007; 30(3):629–37. doi: 10.2337/dc06-2056 PMID: 17327332.

19. Cutillas PR, Chalkley RJ, Hansen KC, Cramer R, Norden AG, Waterfield MD, et al. The urinary proteome in Fanconi syndrome implies specificity in the reabsorption of proteins by renal proximal tubule cells. American journal of physiology Renal physiology. 2004; 287(3):F353–64. doi: 10.1152/ajprenal.00018.2004 PMID: 15140760.

20. Kuroczycza-Sniatytszcz E, Wasilewska A, Sulik A, Milewski R. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity in adolescents with primary hypertension. Pediatric nephrology. 2013;
21. Urquidi V, Goodison S, Kim J, Chang M, Dai Y, Rosser CJ. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology. 2012; 79(5):1185 e1–6. doi: 10.1016/j.urology.2012.01.016 PMID: 22386755; PubMed Central PMCID: PMC3341520.

22. Thongboonkerd V, Klein JB, Pierce WM, Jevans AW, Arthur JM. Sodium loading changes urinary protein excretion: a proteomic analysis. American journal of physiology Renal physiology. 2003; 284(6):F1155–63. doi: 10.1152/ajprenal.00140.2002 PMID: 12582004.

23. Shao C, Li M, Li X, Wei L, Zhu L, Yang F, et al. A tool for biomarker discovery in the urinary proteome: a manually curated human and animal urine protein biomarker database. Molecular & cellular proteomics: MCP. 2011; 10(11):M111 010975. doi: 10.1074/mcp.M111.010975 PMID: 21876203; PubMed Central PMCID: PMC3226410.

24. Harrison-Bernard LM. The renal renin-angiotensin system. Advances in physiology education. 2009; 33(4):270–4. doi: 10.1152/advan.00049.2009 PMID: 19948673.

25. McAreavey D, Cumming AM, Sood VP, Leckie BJ, Morton JJ, Murray GD, et al. The effect of oral prazosin on blood pressure and plasma concentrations of renin and angiotensin II in man. Clinical science. 1981; 61 Suppl 7:457s–60s . PMID: 7032827.

26. Quaye IK. Haptoglobin, inflammation and disease. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008; 102(8):735–42. doi: 10.1016/j.trstmh.2008.04.010 PMID: 18486167.

27. Weinberger MH, Miller JZ, Fineberg NS, Luft FC, Grim CE, Christian JC. Association of haptoglobin with sodium sensitivity and resistance of blood pressure. Hypertension. 1987; 10(4):443–6. PMID: 3653973.

28. Yoo C, Yoon DH, Kim S, Huh J, Park CS, Park CJ, et al. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. Hematological oncology. 2015. doi: 10.1002/hon.2188 PMID: 25689467.

29. Musialik D, Raszeja-Wanic B, Giuszek J, Pieczynska A. [Excretion of beta-2-microglobulin in hypertension]. Polski tygodnik lekarski. 1994; 49(10–11):239–41. PMID: 7862587.

30. Wang L, Chen S, Zhang M, Li N, Chen Y, Su W, et al. Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer. Journal of cellular biochemistry. 2012; 113(8):2679–86. doi: 10.1002/jcb.24143 PMID: 22441772.

31. Lewen S, Zhou H, Hu HD, Cheng T, Markowitz D, Reisfeld RA, et al. A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer immunology, immunotherapy: CII. 2008; 57(4):507–15. doi: 10.1007/s00262-007-0389-x PMID: 17786443.

32. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1995; 13(5):26–32. PMID: 7799029.

33. Beutler E, Gelbart T. Plasma glutathione in health and in patients with malignant disease. The Journal of laboratory and clinical medicine. 1985; 105(5):581–4. PMID: 3989350.

34. Li X, Zhao M, Li M, Jia L, Gao Y. Effects of three commonly-used diuretics on the urinary proteome. Genomics, proteomics & bioinformatics. 2014; 12(3):120–6. doi: 10.1016/j.gpb.2013.12.002 PMID: 24508282; PubMed Central PMCID: PMC4411397.

35. Li M, Zhao M, Gao Y. Changes of proteins induced by anticoagulants can be more sensitively detected in urine than in plasma. Science China Life sciences. 2014; 57(7):649–56. doi: 10.1007/s11427-014-4661-y PMID: 24907934.